PMID- 36403055
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20221123
IS  - 1475-2867 (Print)
IS  - 1475-2867 (Electronic)
IS  - 1475-2867 (Linking)
VI  - 22
IP  - 1
DP  - 2022 Nov 19
TI  - Role of CC-chemokine ligand 2 in gynecological cancer.
PG  - 361
LID - 10.1186/s12935-022-02763-z [doi]
LID - 361
AB  - Gynecological cancer is one of the most severe diseases that threaten the lives 
      and health of women worldwide. Its incidence rate increases with each passing 
      year and becomes more prevalent among young people. The prognosis of 
      gynecological cancer remains poor despite significant advances in surgical 
      removal and systemic chemotherapy. Several chemokines play a role in the 
      progression of gynecologic cancers. CCL2 (CC-chemokine ligand 2), also termed 
      MCP-1 (monocyte chemotactic protein 1), plays a significant physiological role in 
      monocyte cell migration and the inflammatory response. Recent studies have 
      demonstrated that CCL2 plays a pro-tumorigenic function in the tumor 
      microenvironment. According to previous studies, CCL2 plays a significant role in 
      the occurrence and development of gynecological cancers. Furthermore, recent 
      studies noted that CCL2 could be a potential diagnostic biomarker and prognostic 
      predictor. The purpose of this paper is to review the role of CCL2 in the 
      occurrence and development of gynecological cancers and to discuss the potential 
      therapeutic strategy of CCL2 for gynecological cancers, with a primary focus on 
      breast cancer, ovarian cancer, cervical cancer, and endometrial cancer.
CI  - (c) 2022. The Author(s).
FAU - Zhang, Jia-Jia
AU  - Zhang JJ
AD  - College of Life Sciences, Henan Agricultural University, Zhengzhou, 450002, 
      China.
FAU - Liu, Wei
AU  - Liu W
AD  - College of Life Sciences, Henan Agricultural University, Zhengzhou, 450002, 
      China.
FAU - Xing, Guo-Zhen
AU  - Xing GZ
AD  - College of Life Sciences, Henan Agricultural University, Zhengzhou, 450002, 
      China.
FAU - Xiang, Li
AU  - Xiang L
AD  - Henan Provincial People's Hospital/People's Hospital of Zhengzhou University, 7 
      Weiwu Road, Jinshui District, Zhengzhou, 450000, China.
FAU - Zheng, Wen-Ming
AU  - Zheng WM
AD  - College of Life Sciences, Henan Agricultural University, Zhengzhou, 450002, 
      China.
FAU - Ma, Zhen-Ling
AU  - Ma ZL
AD  - College of Life Sciences, Henan Agricultural University, Zhengzhou, 450002, 
      China. xmzl@henau.edu.cn.
LA  - eng
GR  - 30500424/the Young Talents Program of Henan Agricultural University/
GR  - 30500618/the Young Talents Program of Henan Agricultural University/
GR  - 31802164/the National Natural Science Foundation of China/
GR  - 22A180017/the Key scientific research project of Henan Province/
GR  - 212102310898/Scientific and Technological Research Project of Henan Province/
GR  - 222300420177/the Natural Science Foundation of Henan Province/
PT  - Journal Article
PT  - Review
DEP - 20221119
PL  - England
TA  - Cancer Cell Int
JT  - Cancer cell international
JID - 101139795
PMC - PMC9675065
OTO - NOTNLM
OT  - Breast cancer
OT  - CCL2
OT  - CCL2/CCR2 axis
OT  - Cervical cancer
OT  - Ovarian cancer
COIS- The authors declare no competing interests.
EDAT- 2022/11/20 06:00
MHDA- 2022/11/20 06:01
PMCR- 2022/11/19
CRDT- 2022/11/19 23:59
PHST- 2022/01/17 00:00 [received]
PHST- 2022/10/25 00:00 [accepted]
PHST- 2022/11/19 23:59 [entrez]
PHST- 2022/11/20 06:00 [pubmed]
PHST- 2022/11/20 06:01 [medline]
PHST- 2022/11/19 00:00 [pmc-release]
AID - 10.1186/s12935-022-02763-z [pii]
AID - 2763 [pii]
AID - 10.1186/s12935-022-02763-z [doi]
PST - epublish
SO  - Cancer Cell Int. 2022 Nov 19;22(1):361. doi: 10.1186/s12935-022-02763-z.